Effect of levosimendan on long-term prognosis in patients with myocardial infarction and concomitant chronic brain ischemia

Aim. To study the effect of levosimendan (LS) on 1-year prognosis in patients with myocardial infarction (MI), complicated with heart failure (HF), and concomitant chronic brain ischemia (CBI).

Material and methods. The study included 182 patients with Q-wave MI, complicated by HF with left ventricular ejection fraction (LVEF)<40%, and concomitant CBI (149 (81,9%) men and 33 (18,1%) women). The median age was 60,4 (53; 69) years. Group I (control) included 49 patients who received standard therapy; group II (experimental) — 133 patients who were injected with LS on days 1-2 of MI. All patients underwent echocardiography, duplex ultrasound of peripheral arteries and were examined by angioneurologist. A year later, the hard endpoints of recurrent MI, angina progression, revascularization, acute decompensated HF, rehospitalizations, strokes, and death were assessed.

Results. According to multivariate regression analysis, LS administered in the acute period of myocardial infarction reduced the risk of hard endpoints (hazard ratio, 0,32,95% confidence interval, 0,2-0,52, p=0,001), but did not affect patient survival.

Conclusion. In patients with MI complicated by left ventricular failure and associated with CBI, LS infusion in the acute period of MI can reduce the risk of adverse cardiovascular events during the year.

1. Lam CSP, Gamble GD, Ling LH, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur. Heart J. 2018;39(20):1770-80. doi:10.1093/eurheartj/ehy005.

2. Akimova NS, Persashvili DG, Martynovich TV, Shvarc JuG. Cognitive disorders and the state of the gray matter of the brain in heart failure on the background of CHD. Zhurnal serdechnaja nedostatochnost’. 2011;12(5):282-5. (In Russ.)

3. Postley JE, Luo Y, Wong ND, Gardin JM. Identification by ultrasound evaluation of the carotid and femoral arteries of high-risk subjects missed by three validated cardiovascular disease risk algorithms. Am J Cardiol. 2015;116(10):1617-1623. doi:10.1016/j.amjcard.2015.08.031.

4. Sumin AN, Kuhareva IN, Trubnikova OA, Kovalenko AV. Stenosis of carotid arteries in patients with ischemic stroke: prevalence, severity, factors associated with their presence. Kompleksnye problemy serdechno-sosudistyh zabolevanij. 2013;(3):12-7. (In Russ.) doi:10.17802/2306-1278-2013-3-12-17.

5. Silvetti S, Nieminen MS. Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis. ESC Heart Fail. 2017;4(4):595-604. doi:10.1016/j.ijcard.2015.08.188.

6. Onichimowski D, Nosek K, Goraj R. Use of levosimendan in the treatment of cerebral vascular vasospasm: a case study. Drug Des Devel Ther. 2018;12:1777-83. doi:10.2147/DDDT.S158237.

7. Roehl AB, Zoremba N, Kipp M, et al. The effects of levosimendan on brain metabolism during initial recovery from global transient ischaemia/hypoxia. BMC Neurol. 2012;12:81. doi:10.1186/1471-2377-12-81.

8. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) Eur Heart J. 2002;23(18):1422-32. doi:10.1053/euhj.2001.3158.

9. Lehtonen L, Poder P. The utility of levosimendan in the treatment of heart failure. Ann Med. 2007;39(1):2-17. doi:10.1080/07853890601073346.

10. Mebazaa A, Nieminen MS, Filippatos GS, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail. 2009;11(3):304-11. doi:10.1093/eurjhf/hfn045.

11. Garratt C, Packer M, Colucci W, et al. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study. Crit Care. 2004;8:89. doi:10.1186/cc2556.

12. Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta analysis of randomized controlled studies. Crit Care Med. 2012;40(2):634-46. doi:10.1097/CCM.0b013e318232962a.

13. Polzl G, Allipour Birgani S, Comm-Colet J, et al. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period. ESC Heart Fail. 2019;6(1):174-81. doi:10.1002/ehf2.12366.

14. Nieminen MS, Buerke M, Cohen-Solal A, et al. Role of levosimendan in the treatment of acute heart failure complicating the acute coronary syndrome: review and consensus of experts. Int J Cardiol. 2016:1(218):150-7. doi:10.1016/j.ijcard.2016.05.009.

15. Fedorova MV, Petrova EB, Fedorova KV. The effect of levosimendan on patients with a low ejection fraction of the left ventricle during acute decompensation of heart failure. Medicinskij Al’manah. 2016;14(4):74-79. (In Russ.)